DJIA 16,014.38 -12.67 -0.08%
NASDAQ 4,268.76 -14.99 -0.35%
S&P 500 1,852.21 -1.23 -0.07%
market minute promo

ImmunoGen (NASDAQ: IMGN)

7.13 0.01 (0.14%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

IMGN $7.13 0.14%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.94
Previous Close $7.12
Daily Range $6.78 - $7.44
52-Week Range $6.78 - $19.43
Market Cap $620.2M
P/E Ratio -4.94
Dividend (Yield) $0.00 (0.0%)
Volume 743,349
Average Daily Volume 1,117,450
Current FY EPS -$1.36




Drug Makers

ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website:

News & Commentary

ImmunoGen, Inc.'s Earnings Play the Amortization Blues

Keep focused on the pipeline because revenue and earnings are going to be bumpy for some time.

ImmunoGen/Merck Collaborate for Ovarian Cancer Study

ImmunoGen Posts Wider-than-Expected Loss, Retains View

ImmunoGen (IMGN) Reports Wider-than-Expected Loss

ImmunoGen's (IMGN) CEO Dan Junius on Q2 2016 Results - Earnings Call Transcript

ImmunoGen (IMGN) Q4 2015 Results - Earnings Call Webcast

ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect?

Health Care Sector Update for 01/26/2016: IMGN, QGEN

Why BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc, and ImmunoGen, Inc. Got Clobbered Today

Investors are shunning biotechs in 2016.

ImmunoGen, Inc. Shares Fall After It Outlines Its 2016 Clinical Events Outlook

Shares dipped 10% after the company issued a press release examining its 2015 accomplishments and its expectations in 2016.

See More IMGN News...

IMGN's Top Competitors

IMGN $7.13 (0.14%)
Current stock: IMGN
AMGN $143.16 (0.11%)
Current stock: AMGN
GILD $87.25 (2.33%)
Current stock: GILD
BIIB $249.99 (-0.31%)
Current stock: BIIB